Research Analysts’ Weekly Ratings Changes for BioMarin Pharmaceutical (BMRN)

BioMarin Pharmaceutical (NASDAQ: BMRN) has recently received a number of price target changes and ratings updates:

• 9/9/2024 – BioMarin Pharmaceutical had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $110.00 price target on the stock.
• 9/5/2024 – BioMarin Pharmaceutical had its “sector perform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $100.00 price target on the stock.
• 9/5/2024 – BioMarin Pharmaceutical had its price target raised by analysts at Scotiabank from $86.00 to $95.00. They now have a “sector perform” rating on the stock.
• 9/5/2024 – BioMarin Pharmaceutical had its price target raised by analysts at JPMorgan Chase & Co. from $111.00 to $120.00. They now have an “overweight” rating on the stock.
• 9/5/2024 – BioMarin Pharmaceutical had its price target raised by analysts at Piper Sandler from $107.00 to $122.00. They now have an “overweight” rating on the stock.
• 9/5/2024 – BioMarin Pharmaceutical had its price target lowered by analysts at Truist Financial Co. from $140.00 to $118.00. They now have a “buy” rating on the stock.
• 8/30/2024 – BioMarin Pharmaceutical was upgraded by analysts at William Blair to a “strong-buy” rating.
• 8/27/2024 – BioMarin Pharmaceutical had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $107.00 price target on the stock.
• 8/21/2024 – BioMarin Pharmaceutical had its price target raised by analysts at Stifel Nicolaus from $112.00 to $115.00. They now have a “buy” rating on the stock.
• 8/20/2024 – BioMarin Pharmaceutical was upgraded by analysts at Sanford C. Bernstein from a “market perform” rating to an “outperform” rating. They now have a $110.00 price target on the stock, up previously from $94.00.
• 8/8/2024 – BioMarin Pharmaceutical was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 8/6/2024 – BioMarin Pharmaceutical had its price target raised by analysts at Scotiabank from $85.00 to $86.00. They now have a “sector perform” rating on the stock.
• 8/6/2024 – BioMarin Pharmaceutical had its “sector perform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $100.00 price target on the stock.
• 8/6/2024 – BioMarin Pharmaceutical had its price target lowered by analysts at Barclays PLC from $111.00 to $110.00. They now have an “overweight” rating on the stock.
• 8/6/2024 – BioMarin Pharmaceutical had its price target raised by analysts at Evercore ISI from $113.00 to $115.00. They now have an “outperform” rating on the stock.
• 8/6/2024 – BioMarin Pharmaceutical had its price target lowered by analysts at TD Cowen from $125.00 to $120.00. They now have a “buy” rating on the stock.
• 8/6/2024 – BioMarin Pharmaceutical had its price target raised by analysts at Stifel Nicolaus from $108.00 to $112.00. They now have a “buy” rating on the stock.
• 8/5/2024 – BioMarin Pharmaceutical had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $110.00 price target on the stock.
• 7/30/2024 – BioMarin Pharmaceutical was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 7/25/2024 – BioMarin Pharmaceutical had its “hold” rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $89.00 price target on the stock.
• 7/22/2024 – BioMarin Pharmaceutical had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $110.00 price target on the stock.
• 7/22/2024 – BioMarin Pharmaceutical was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.

BioMarin Pharmaceutical Stock Performance

Shares of BMRN stock opened at $84.38 on Friday. The stock has a fifty day moving average price of $86.77 and a 200 day moving average price of $84.92. The stock has a market cap of $16.02 billion, a PE ratio of 78.86, a P/E/G ratio of 1.02 and a beta of 0.31. BioMarin Pharmaceutical Inc. has a 1 year low of $73.68 and a 1 year high of $99.56. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.95 and a current ratio of 3.05.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings data on Monday, August 5th. The biotechnology company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.39. The firm had revenue of $712.03 million during the quarter, compared to analysts’ expectations of $660.51 million. BioMarin Pharmaceutical had a return on equity of 6.91% and a net margin of 9.91%. Sell-side analysts forecast that BioMarin Pharmaceutical Inc. will post 2.4 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioMarin Pharmaceutical

A number of institutional investors have recently made changes to their positions in the stock. Envestnet Portfolio Solutions Inc. raised its holdings in shares of BioMarin Pharmaceutical by 1.2% in the first quarter. Envestnet Portfolio Solutions Inc. now owns 10,668 shares of the biotechnology company’s stock worth $932,000 after acquiring an additional 130 shares during the last quarter. Quent Capital LLC raised its holdings in shares of BioMarin Pharmaceutical by 58.9% in the second quarter. Quent Capital LLC now owns 391 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 145 shares during the last quarter. Yousif Capital Management LLC raised its holdings in shares of BioMarin Pharmaceutical by 8.9% in the first quarter. Yousif Capital Management LLC now owns 2,414 shares of the biotechnology company’s stock worth $211,000 after acquiring an additional 198 shares during the last quarter. Integrated Advisors Network LLC grew its position in shares of BioMarin Pharmaceutical by 6.2% in the fourth quarter. Integrated Advisors Network LLC now owns 3,533 shares of the biotechnology company’s stock valued at $341,000 after purchasing an additional 206 shares during the period. Finally, SteelPeak Wealth LLC grew its position in shares of BioMarin Pharmaceutical by 10.9% in the first quarter. SteelPeak Wealth LLC now owns 2,498 shares of the biotechnology company’s stock valued at $218,000 after purchasing an additional 246 shares during the period. 98.71% of the stock is owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.